The stock of Endologix, Inc. (NASDAQ:ELGX) is a huge mover today! About 406,803 shares traded hands. Endologix, Inc. (NASDAQ:ELGX) has risen 41.89% since March 8, 2016 and is uptrending. It has outperformed by 32.57% the S&P500.
The move comes after 6 months negative chart setup for the $1.06 billion company. It was reported on Oct, 11 by Barchart.com. We have $11.63 PT which if reached, will make NASDAQ:ELGX worth $74.20M less.
Analysts await Endologix, Inc. (NASDAQ:ELGX) to report earnings on October, 24. They expect $-0.14 earnings per share, down 7.69% or $0.01 from last year’s $-0.13 per share. After $-0.20 actual earnings per share reported by Endologix, Inc. for the previous quarter, Wall Street now forecasts -30.00% EPS growth.
Endologix, Inc. (NASDAQ:ELGX) Ratings Coverage
Out of 10 analysts covering Endologix Inc. (NASDAQ:ELGX), 8 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 80% are positive. Endologix Inc. has been the topic of 23 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The firm has “Mkt Perform” rating given on Tuesday, September 6 by Leerink Swann. The firm has “Overweight” rating by JP Morgan given on Thursday, August 6. The stock of Endologix, Inc. (NASDAQ:ELGX) earned “Buy” rating by Canaccord Genuity on Monday, June 13. The rating was downgraded by Canaccord Genuity to “Hold” on Tuesday, August 4. The firm has “Outperform” rating by RBC Capital Markets given on Tuesday, February 23. The firm has “Market Perform” rating given on Tuesday, October 27 by BMO Capital Markets. The rating was reinitiated by JP Morgan on Monday, April 4 with “Overweight”. The company was maintained on Tuesday, November 3 by Piper Jaffray. The stock of Endologix, Inc. (NASDAQ:ELGX) has “Buy” rating given on Tuesday, February 2 by Stifel Nicolaus. The company was initiated on Tuesday, October 27 by Canaccord Genuity.
According to Zacks Investment Research, “Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis.”
Insitutional Activity: The institutional sentiment increased to 1.96 in 2016 Q2. Its up 0.27, from 1.69 in 2016Q1. The ratio improved, as 19 funds sold all Endologix, Inc. shares owned while 29 reduced positions. 41 funds bought stakes while 53 increased positions. They now own 88.15 million shares or 13.23% more from 77.85 million shares in 2016Q1.
Creative Planning holds 0% of its portfolio in Endologix, Inc. (NASDAQ:ELGX) for 1,900 shares. Royal State Bank Of Canada owns 2,465 shares or 0% of their US portfolio. Peak6 Investments Limited Partnership accumulated 18,147 shares or 0% of the stock. Plante Moran Financial Advsrs Ltd Liability Company reported 1,661 shares or 0.02% of all its holdings. Fmr Limited Com has 0% invested in the company for 1.28 million shares. Essex Woodlands Ventures Inc holds 5.59% of its portfolio in Endologix, Inc. (NASDAQ:ELGX) for 1.26M shares. Pub Employees Retirement Association Of Colorado owns 23,927 shares or 0% of their US portfolio. Partner Mngmt Limited Partnership holds 0.65% or 31,800 shares in its portfolio. Diam accumulated 0.05% or 257,104 shares. Lord Abbett Communications Ltd Liability Corporation reported 376,731 shares or 0.01% of all its holdings. Ameriprise Fincl Inc accumulated 1.16 million shares or 0.01% of the stock. Natl Bank Of Montreal Can holds 0% of its portfolio in Endologix, Inc. (NASDAQ:ELGX) for 705 shares. Millennium Management Ltd reported 952,798 shares or 0.03% of all its holdings. Partner Fund Mngmt Ltd Partnership has 1.56 million shares for 0.59% of their US portfolio. Highbridge Limited Liability Company, a New York-based fund reported 24,010 shares.
Insider Transactions: Since May 26, 2016, the stock had 0 insider buys, and 10 selling transactions for $519,081 net activity. 14,000 shares were sold by Chobotov Michael V., worth $173,600 on Friday, August 5. Another trade for 689 shares valued at $8,647 was made by DePalma Amanda L. on Wednesday, June 1. $76,756 worth of Endologix, Inc. (NASDAQ:ELGX) shares were sold by McDermott John D. Shares for $28,790 were sold by Mitchell Robert D. Shares for $12,010 were sold by Lima Jose A.. On Friday, June 3 WALLER GREGORY D sold $100,308 worth of the stock or 7,800 shares. $12,010 worth of Endologix, Inc. (NASDAQ:ELGX) was sold by DeJohn Joseph A. on Wednesday, June 1.
More news for Endologix, Inc. (NASDAQ:ELGX) were recently published by: Fool.com, which released: “Why Endologix, Inc. Is Down 13% Today” on August 03, 2016. Globenewswire.com‘s article titled: “Endologix, Inc. and TriVascular Technologies, Inc. Complete Merger” and published on February 03, 2016 is yet another important article.
ELGX Company Profile
Endologix, Inc., incorporated on June 2, 1993, is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). The Company’s EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). Sales of the Company’s EVAR and EVAS platforms (including extensions and accessories) to hospitals in the United States and Europe, and to third-party international distributors provide the sole source of its revenue. It offers various accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.